Plaque Psoriasis Pipeline Analysis Report 2025

According to the World Psoriasis Day consortium, 2-3% of the world's population has some form of psoriasis and approximately 30% of people with psoriasis develop psoriatic arthritis. 6.7 million adults are affected by plague psoriasis globally and 1-2% of the population is affected in the United States. To address a wider section of patients and develop high-efficacy drug alternatives, several companies are engaged in research initiatives. This is boosting the drug development landscape significantly.

Report Coverage

The Plaque Psoriasis Drug Pipeline Insight Report by the publisher gives comprehensive insights into plaque psoriasis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for plaque psoriasis. The plaque psoriasis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The plaque psoriasis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with plaque psoriasis treatment guidelines to ensure optimal care practices.

The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing plaque psoriasis pipeline development activities are covered. Moreover, plaque psoriasis collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.

Plaque Psoriasis Pipeline Outlook

Plaque psoriasis or psoriasis vulgaris is a chronic autoimmune disorder that causes cells to reproduce very quickly. The most common affected areas are elbows, back, knees and scalp among others. Plaque psoriasis is an immune disorder wherein the immune response overreacts, causing inflammation and leading to the rapid growth of new skin cells. New skin cells grow every 28-30 days, but in people suffering from plaque psoriasis, new cells grow and move to the skin's surface every 3-4 days. The buildup of new cells replacing old cells creates plaques. The disease can affect anyone, however, the white population is more prone to the condition. The symptoms of plaque psoriasis include the appearance of raised, discolored plaques with a white or silvery surface, bleeding, cracks, itchiness and irritation or pain among others.

To treat plague psoriasis with mild symptoms, creams, lotion, or gel such as anthralin, coal tar, corticosteroids, salicylic acid are commonly prescribed. In severe cases, healthcare providers may recommend medicinal injections such as adalimumab, etanercept or Ustekinumab, or oral medicines such as acitretin, cyclosporine or methotrexate. Depending on the patient profile, procedures like phototherapy can also be advised. It uses ultraviolet light, usually ultraviolet B from special lamps. Moreover, several companies and institutes are developing novel therapies to manage the disease. For instance, a trial is investigating whether people with plaque psoriasis can take an oral treatment to manage and improve the condition. The presence of large clinical trials for plaque psoriasis has influenced the pipeline landscape positively.

Plaque Psoriasis - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of plaque psoriasis drug candidates based on several segmentations including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase.

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The plaque psoriasis therapeutics assessment report covers 50+ drug analyses based on drug classes:

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Plaque psoriasis - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total clinical trials for plaque psoriasis with 278 pipeline drugs in phase III.

Plaque psoriasis - Pipeline Assessment Segmentation, By Drug Classes

The drug molecules categories covered under plaque psoriasis pipeline analysis include antibody, antisense oligonucleotides, immunotherapy, monoclonal antibody, peptides, protein, recombinant protein, small molecule, stem cell and vaccine. Several trials are ongoing to assess the efficacy of immunotherapies. Studies show that targeted biological immunotherapies have been highly effective in controlling skin disease in patients with psoriasis. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for plaque psoriasis.

Plaque Psoriasis Clinical Trials Assessment - Competitive Dynamics

The plaque psoriasis drug report insights involve the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in plaque psoriasis clinical trials:

• Power Life Sciences Inc.
• Evelo Biosciences, Inc.
• Artax Biopharma Inc
• Bristol-Myers Squibb
• Dermavant Sciences, Inc.
• Alza Corporation, DE, USA
• Arcutis Biotherapeutics, Inc.
• Shanghai Celgen Bio-Pharmaceutical Co.,Ltd
• Amgen
• Novartis Pharmaceuticals
• Huabo Biopharm Co., Ltd.
• Galderma R&D
• Others

Plaque Psoriasis - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for plaque psoriasis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of plaque psoriasis drug candidates.

Drug: EDP1815

The trial is designed to investigate the clinical efficacy of EDP1815 and to identify an optimal dose in people with mild to moderate psoriasis. The trial is sponsored by Evelo Biosciences Inc. and is currently under phase II.

Drug: AX-158

The objective of the study is to assess the safety and tolerability of AX-158 in patients with mild to moderate psoriasis. The trial is sponsored by Artax Biopharma Inc. and is currently under phase II.

Drug: Cetaphil

Galderma R&D is developing the drug and is currently under phase IV. The study is being designed to evaluate the efficacy of a topical skincare regimen conducted at 2 weeks, 4 weeks, and 8 weeks post-baseline.

Reasons To Buy This Report

The Plaque psoriasis Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for plaque psoriasis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into plaque psoriasis collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.

Key Questions Answered in the Plaque Psoriasis - Pipeline Assessment Report

• Which companies/institutions are leading the plaque psoriasis drug development?
• What is the efficacy and safety profile of plaque psoriasis pipeline drugs?
• Which company is leading the plaque psoriasis pipeline development activities?
• What is the current plaque psoriasis commercial assessment?
• What are the opportunities and challenges present in the plaque psoriasis drug pipeline landscape?
• What is the efficacy and safety profile of plaque psoriasis pipeline drugs?
• Which company is conducting major trials for plaque psoriasis drugs?
• Which companies/institutions are involved in plaque psoriasis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in plaque psoriasis?

This product will be delivered within 3-5 business days.